Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track FENC with free AI briefings, catalyst countdowns, and dilution alerts.

FENC · FENNEC PHARMACEUTICALS INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$48.7M Cash on Hand
CF+ Cash Runway
Follow FENC by email Get an email when FENC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about FENC, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sodium Thiosulfate
FDA approved Sep 2022 · Pedmark
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk… N/A · NCT04132882 Available
Pedmark® STS Solid Tumor Malignancies Phase 1/2 · NCT07407582 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

FENC holds $48.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 14 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FENC files for a raise →

👥 Who Owns FENC

Insiders 1.6% Other 5%+ holders 9.4% Institutions (162 holders) 57.3% Public and other holders 31.7%
HolderTypeShares% of sharesAs of
Rosalind Advisors, Inc. 5%+ holder (13G) 3,321,333 9.41% 2026-06-30
Orin Hirschman Institution (13G, 5%+) 2,499,421 7.08% 2026-09-30
Robert Andrade
CHIEF FINANCIAL OFFICER · +779,330 options
Insider 248,558 0.70% 2026-10-31
Rosty Raykov
Former Director
Insider 124,411 0.35% 2026-08-31
Jeffrey S. Hackman
Chief Executive Officer, Director
Insider 70,844 0.20% 2026-10-31
Chris A Rallis
Director · +200,000 options
Insider 63,077 0.18% 2026-05-11
Christiana Marie Cioffi
Chief Strategy Officer
Insider 28,902 0.08% 2026-10-31
Terry L Evans
Chief Commercial Officer
Insider 24,181 0.07% 2026-10-31
Pierre Sargis Sayad
Chief Medical Officer
Insider 13,701 0.04% 2026-10-31

Share count 35,305,117 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full FENC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FENC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.